Literature DB >> 20132884

A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies.

Lin Mei1, Junbo Bao, Lina Tang, Chao Zhang, Hai Wang, Leilei Sun, Guilei Ma, Laiqiang Huang, Jing Yang, Linhua Zhang, Kexin Liu, Cunxian Song, Hongfan Sun.   

Abstract

The objective of this study was to prepare a novel mifepristone-loaded PCL/Pluronic F68 implant to achieve long-term treatment of endometriosis. PCL/Pluronic F68 compound (90/10, w/w) with viscosity average molecular weight of 65,000 was successfully synthesized. The end-capped Pluronic F68 was incorporated in PCL matrixes as molecular dispersion without forming a copolymer. The mifepristone-loaded implant made of PCL/Pluronic F68 compound was a cylindrical capsule with an outer diameter of 2.5mm and an inner diameter of 2.2mm. The surface of PCL/Pluronic F68 compound appears porous because Pluronic F68 which is water soluble could leach out due to the water phase. Drug loading of 0.75-, 1.5- and 3.0-cm length implants was 3.05+/-0.18, 6.06+/-0.41 and 11.87+/-0.39mg, respectively. A sustained mifepristone release rate without obvious initial burst and later decline over a period of 180d was observed. The cumulative drug release showed a linear relationship with time, indicating that mifepristone release from the implants followed zero-order kinetics (R(2)>0.99). The data showed that the C(max) and AUC(0-inf) were proportional to imlant length and dose, and all groups reached plasma C(max) at about the same time (approximately 7d) and had similar T(1/2) (approximately 150d) and MRT (approximately 220d). There were obvious inhibitory effects on the growth of endometrial explants in Wister rats in a dose-dependent manner after administration of mifepristone-loaded implants with implant length from 1.5 to 9.0cm for 1-3 months. However, mifepristone-loaded implants with implant length of 12.0cm had no better inhibitory effects on the growth of endometrium when compared with the implants with implant length of 9.0cm (P>0.05). In conclusion, subcutaneous implantation of mifepristone-loaded PCL/Pluronic F68 capsules was proven an effective means for long-term treatment of chronic endometriosis. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132884     DOI: 10.1016/j.ejps.2010.01.012

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

Review 1.  Endometriosis and nuclear receptors.

Authors:  Bahar D Yilmaz; Serdar E Bulun
Journal:  Hum Reprod Update       Date:  2019-07-01       Impact factor: 15.610

2.  Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex.

Authors:  Suhong Yu; Xingtian Yang; Yewei Zhu; Fangwei Xie; Yusheng Lu; Ting Yu; Cuicui Yan; Jingwei Shao; Yu Gao; Fan Mo; Guoneng Cai; Patrick J Sinko; Lee Jia
Journal:  Sci Rep       Date:  2015-01-19       Impact factor: 4.379

Review 3.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

Review 4.  Organs-On-Chip Models of the Female Reproductive System.

Authors:  Vanessa Mancini; Virginia Pensabene
Journal:  Bioengineering (Basel)       Date:  2019-11-07

Review 5.  Medical treatments for endometriosis-associated pelvic pain.

Authors:  Gabriella Zito; Stefania Luppi; Elena Giolo; Monica Martinelli; Irene Venturin; Giovanni Di Lorenzo; Giuseppe Ricci
Journal:  Biomed Res Int       Date:  2014-08-07       Impact factor: 3.411

6.  Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure.

Authors:  Fernando M Reis; Larissa M Coutinho; Silvia Vannuccini; Frédéric Batteux; Charles Chapron; Felice Petraglia
Journal:  Hum Reprod Update       Date:  2020-06-18       Impact factor: 15.610

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.